MedImmune Named One Of Maryland's Fastest Growing Technology Companies In Deloitte Technology Fast 50 Program

GAITHERSBURG, Md., Oct. 12  /PRNewswire-FirstCall/ -- MedImmune, Inc. has been named to Deloitte's Maryland Technology Fast 50 program for the ninth consecutive year.  The Technology Fast 50 is a ranking of the fastest-growing technology companies in the area by Deloitte & Touche LLP. Rankings are based on the percentage growth over five years from 2000-2004.

"We are proud to again be named by Deloitte & Touche as one of the area's fastest growing companies," said Lota S. Zoth, MedImmune's chief financial officer. "In 2004, MedImmune's core business continued to achieve solid growth, with product sales surpassing $1 billion for the first time in the company's history. We also made significant advances in our clinical pipeline, with three programs moving into Phase 3 development."

"Deloitte's Maryland Technology Fast 50 companies have shown the strength, vision and temerity to succeed in today's very competitive technology environment," said Andrew Harrs, principal, Deloitte & Touche LLP in McLean, Virginia, and southeast region telecommunications, media and technology practice leader. "We applaud the success of MedImmune and acknowledge it as one of the very few to accomplish such a fast growth rate over the past five years."

Along with Deloitte & Touche LLP, the Maryland Technology Fast 50 program is hosted by Wilmer Cutler Pickering Hale and Dorr. Media sponsors include PR Newswire and WTOP Radio Network.

To qualify for the Technology Fast 50, companies must have had operating revenues of at least $50,000 in 2000 and $1,000,000 in 2004, be headquartered in North America, and be a "technology company," defined as a company that owns proprietary technology that contributes to a significant portion of the company's operating revenues; or devotes a significant proportion of revenues to research and development of technology.

Winners of the 15 regional Technology Fast 50 programs in the United States and Canada are automatically entered in the Deloitte Technology Fast 500 program, which ranks North America's top 500 fastest growing technology companies. For more information on the Fast 50 or Fast 500 programs, visit http://www.fast500.com/.

About MedImmune

MedImmune strives to provide better medicines to patients, new medical options for physicians, rewarding careers to employees, and increased value to shareholders. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious diseases, cancer and inflammatory diseases. With approximately 2,000 employees worldwide, MedImmune is headquartered in Maryland. For more information, visit the company's website at http://www.medimmune.com/.

About Deloitte

Deloitte refers to one or more of Deloitte Touche Tohmatsu, a Swiss Verein, its member firms, and their respective subsidiaries and affiliates. Deloitte Touche Tohmatsu is an organization of member firms around the world devoted to excellence in providing professional services and advice, focused on client service through a global strategy executed locally in nearly 150 countries. With access to the deep intellectual capital of 120,000 people worldwide, Deloitte delivers services in four professional areas - audit, tax, consulting and financial advisory services - and serves more than one-half of the world's largest companies, as well as large national enterprises, public institutions, locally important clients and successful, fast-growing global growth companies. Services are not provided by the Deloitte Touche Tohmatsu Verein, and, for regulatory and other reasons, certain member firms do not provide services in all four professional areas.

As a Swiss Verein (association), neither Deloitte Touche Tohmatsu nor any of its member firms has any liability for each other's acts or omissions. Each of the member firms is a separate and independent legal entity operating under the names "Deloitte," "Deloitte & Touche," "Deloitte Touche Tohmatsu" or other related names.

This announcement may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties.  Such statements reflect management's current views and are based on certain assumptions.  Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties discussed in the company's filings with the U.S. Securities and Exchange Commission. The company is developing several products for potential future marketing.  There can be no assurance that such development efforts will succeed, that such products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success. 

DATASOURCE: MedImmune, Inc.



CONTACT: Media, Jamie Lacey, [phone], or Investors, Peter Vozzo,

[phone], or John Filler, [phone], all of MedImmune, Inc. 



Web site:  http://www.medimmune.com/

http://www.fast500.com/ 

Copyright